SOPHSOPHiA GENETICS SA
Next earnings Aug 3, 2026 · consensus $-0.23 EPS, $22.1M rev
$5.65
▼ -2.92%$5.65▲ +61.89%
over 1Y
L $3.11H $5.98
Today
-2.9%
1W
+5.8%
1M
+8.2%
3M
+20.2%
YTD
+21.0%
1Y
+61.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy
Mixed signals in the latest filings.
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow SOPH (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
SOPHiA GENETICS SA shows limited reported revenue.
On these fundamentals, SOPH screens as SELL on the SEC figures.
Is SOPH a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 5.5 @ ~0.65 est
- Short put 5 @ ~0.41 est
debit $24max +$26max −$24BE 5.26
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financialsannual, by fiscal year
No income data filed.
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$488M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗4Period ending 2026-07-072026-07-08open ↗144Filing2026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗4Period ending 2026-07-062026-07-07open ↗144Filing2026-07-06open ↗144Filing2026-07-06open ↗
Frequently asked
- Is SOPHiA GENETICS SA (SOPH) a buy?
- SOPH currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is SOPHiA GENETICS SA's quality score?
- SOPH scores 79.30126002290952/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001840706, latest 4 filed 2026-07-08) · EODHD · as of 7/11/2026, 11:25:02 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 11, 2026, 7:25 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
SEC correspondence
SEC · UPLOAD / CORRESPSOPH SEC comment-letter history — every letter and response →
SEC staff comment letters (UPLOAD) questioning the company’s disclosures and its written responses (CORRESP), from the SEC’s filing review. Reviews are routine and this is not an assertion of wrongdoing; correspondence is released about 20 business days after a review concludes, so dates reflect the letter itself, not its release. Source: SEC EDGAR (public domain).